Background:
Obesity has a negative impact on health-related quality of life (HRQoL), related to the severity of obesity. This post-hoc analysis explored the impact of weight loss (WL), over 3 years, on HRQoL in people with prediabetes and obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with hypertension and/or dyslipidaemia.
Methods:
Participants were randomised 2:1 to once-daily SC liraglutide 3.0 mg (n=1505) or placebo (n=749) as adjunct to diet and exercise (NCT01272219). The Short-Form 36 v2 (SF-36) questionnaire was administered in countries with validated translations (79% of participants). Data are reported as estimated change from baseline using ANCOVA with LOCF; increased scores signify improvement for both the physical component score (PSC) and mental component score (MCS). The analysis was stratified by categorical weight change from baseline. Results are reported for both liraglutide 3.0 mg and placebo, as follows: A=weight loss (WL) ≥15%; B=WL 10−14.9%; C=WL 5−9.9%; D=WL 0−4.9%; E=weight gain.
Results:
Baseline characteristics (means): 77.6% female, age 47.9 years, weight 108.2 kg, BMI 39.1 kg/m². A greater proportion of participants treated with liraglutide 3.0 mg vs. placebo were in the higher WL categories: A=10.9 vs 3.1%; B=13.8 vs 6.8%; C=24.7 vs 13.7%; D=35.4 vs 37.3% and E=14.9 vs 38.6%. Changes in PCS were highest in WL category A (6.15) and decreased with decreasing categorical WL: B=3.99; C=4.02; D=2.50; E=0.55 (based on both treatment arms). MCS scores were: A=0.48; B=-0.30; C=-1.08; D=-0.79; E=-1.03.
Conclusions:
More participants achieved greater categorical WL after 3 years with liraglutide 3.0 mg as adjunct to diet and exercise vs. placebo. With greater categorical WL, greater improvements in SF-36 PCS score were observed, corresponding to the 1-year data, while no consistent pattern was observed for MCS.